The Four GLP-1 Price Routes and What Actually Changes on 31 December 2026
Four separate ways to lower the price of a GLP-1 medicine in the United States carry a date stamp pointing at the end of 2026, and if you only read the marketing you would assume all four switch off at midnight on 31 December. That is not what the paperwork says. Three of them do carry a literal 31 December 2026 date in the issuer's own terms, one has already been pushed a year into 2027, and the biggest change of all is not an expiry at all but a price reset that begins the next morning. This piece checks each claim against the manufacturer's own terms pages or the government record, states the conditions attached to every figure, and grades how solid each claim is. It is being published before the reset rather than after it, so the record is in place while the questions are still being asked.
DoseTruth is a price-comparison publisher: it is not a pharmacy, not a telehealth provider, and it does not prescribe or dispense any medication. This is not medical advice and is not a substitute for professional medical guidance, and you should speak to a licensed clinician before starting, stopping, or changing any treatment.
Every price below was checked on 12 September 2026 against the source named beside it. These programmes have been repriced several times across 2025 and 2026, so treat any figure as a snapshot rather than a promise, and if you spot a number that has since moved you can flag it through our contact page. A running view of the wider market sits on the DoseTruth home page.
What actually changes on 31 December 2026?
Three of the four programmes carry an explicit 31 December 2026 end date in their own terms, and the fourth does not end that day at all. The two clear cliffs are the Novo Nordisk introductory self-pay offer and the Eli Lilly commercial savings card. The Lilly self-pay journey card also prints the same 31 December 2026 expiry, though that annual date has been rolled forward before. The Medicare piece is the odd one out, because the demonstration that people call the bridge was extended into 2027, and the genuine Medicare event is a negotiated price that starts on 1 January 2027. The table below states the real status of each, not the marketing version.
| Programme | What it is | Headline price | Real end date in the terms | Primary evidence |
|---|---|---|---|---|
| NovoCare introductory self-pay | Cash price for the two starting Wegovy doses for patients new to the offer | 199 US dollars a month for two fills | 31 December 2026, hard deadline | NovoCare offer page |
| LillyDirect self-pay journey | Cash price for Zepbound vials and KwikPens with a refill condition | 299 to 449 US dollars a month | Card states 31 December 2026, historically renewed | Zepbound savings page, Pharmaceutical Executive |
| Zepbound commercial savings card | Copay support for people with private insurance | As little as 25 US dollars a fill | 31 December 2026, hard deadline | Zepbound savings page |
| Medicare GLP-1 Bridge and the 2027 reset | A temporary Medicare demonstration, then negotiated Part D prices | 50 US dollars a month copay, then a negotiated price | Bridge runs to 31 December 2027, negotiated prices start 1 January 2027 | CMS bridge page, CMS price announcement |
How does the NovoCare 199 dollar introductory offer work, and when does it end?
The NovoCare introductory offer sells the two starting doses of Wegovy at 199 US dollars a month for the first two fills, and it ends on 31 December 2026. According to the NovoCare offer page checked on 12 September 2026, patients new to the Wegovy Savings Offer or to NovoCare Pharmacy pay 199 US dollars for each month of the 0.25 mg and 0.5 mg pens, for two monthly fills, through 31 December 2026. The fine print sets three separate deadlines, all falling around that date. The prescription must be written on or before 31 December 2026, received by the pharmacy by the end of that day, and shipped on or before 31 January 2027.
After those two introductory fills, the price steps up to the standard self-pay rate. The same page lists 349 US dollars a month for Wegovy 0.25 mg through 2.4 mg, and 399 US dollars a month for the higher-strength Wegovy HD 7.2 mg. That 349 figure is itself the product of an earlier cut, since NovoCare Pharmacy launched all doses at 499 US dollars a month before the price was lowered. The oral form of Wegovy is priced separately, at 149 US dollars for the 1.5 mg tablets, 199 US dollars for the 4 mg, and 299 US dollars for the 9 mg and 25 mg tablets, all as of 12 September 2026. We have tracked one of those oral tiers in detail in our audit of the oral Wegovy 4 mg price move from 149 to 199 dollars. The 199 dollar rate is a two-fill trial price, not a maintenance price, and treating it as an ongoing cost is the most common mistake with this offer.
What does LillyDirect self-pay cost, and does the card really expire this year?
LillyDirect self-pay Zepbound is priced by dose with a refill condition attached, and Lilly's own page does print a 31 December 2026 card expiry, though that is an annual date the company has renewed in the past. Pharmaceutical Executive, reporting on Lilly's 1 December 2025 announcement and checked on 12 September 2026, put the self-pay journey prices at 299 US dollars a month for the 2.5 mg strength, 399 US dollars for 5 mg, and 449 US dollars for the 7.5 mg through 15 mg strengths. Those prices depend on a refill discipline that most readers miss. To hold the discounted rate on the higher strengths, the Zepbound savings page checked on 12 September 2026 requires you to complete your next purchase within 45 days of the previous delivery, otherwise regular maintenance prices apply.
Two limits matter more than the headline number. First, the self-pay route is cash only. The terms require you not to seek or accept reimbursement from any third-party payer, including private insurance and any state or federal healthcare programme, which rules out Medicare and Medicaid. Second, the same Zepbound page states plainly that the card expires and savings end on 31 December 2026, and that Lilly may terminate, revoke, or amend the terms at its sole discretion, without notice, and for any reason. So the LillyDirect self-pay date is real on paper, but the durable feature here is the 45-day refill clock, not the calendar year. Whether the 2026 date bites depends on whether Lilly renews the card as it has before, which is exactly why we grade this claim lower than the two hard cliffs.
| Item | Price a month | Condition | Source |
|---|---|---|---|
| Wegovy 0.25 mg and 0.5 mg, intro | 199 US dollars | First two fills, new patients, ends 31 December 2026 | NovoCare offer page |
| Wegovy 0.25 mg to 2.4 mg, standard | 349 US dollars | After the intro fills | NovoCare offer page |
| Wegovy HD 7.2 mg | 399 US dollars | Standard self-pay | NovoCare offer page |
| Oral Wegovy 4 mg | 199 US dollars | Standard self-pay | NovoCare offer page |
| Zepbound 2.5 mg | 299 US dollars | Self-pay journey | Pharmaceutical Executive |
| Zepbound 5 mg | 399 US dollars | Self-pay journey | Pharmaceutical Executive |
| Zepbound 7.5 mg to 15 mg | 449 US dollars | Requires refill within 45 days, else regular price applies | Pharmaceutical Executive, Zepbound savings page |
Which savings card is the one that clearly ends on 31 December 2026?
The Zepbound commercial savings card, for people with private insurance, is the cleanest 31 December 2026 cliff of the four. The Zepbound savings page checked on 12 September 2026 states that eligible commercially insured patients may pay as little as 25 US dollars for a one, two, or three month fill. The savings are capped, at 100 US dollars for a one month fill, 200 US dollars for a two month fill, and 300 US dollars for a three month fill, with a separate annual cap of 1,300 US dollars per calendar year and a limit of 13 fills a year. The same page states the card expires and savings end on 31 December 2026.
The eligibility exclusion is the part that catches people out. You cannot use this card if you are enrolled in any government-funded healthcare programme, and the terms name Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, the Department of Defense, the Department of Veterans Affairs, and TRICARE. That is the standard commercial copay-card carve-out, and it is why this route and the Medicare route below never overlap for a single patient. Novo Nordisk runs a parallel savings card for Wegovy aimed at the same commercially insured group, with its own dose and time limits, so anyone comparing the two brands should read each set of terms rather than assume they match. If you have commercial insurance and use this card, the single most important line to check before the new year is whether Lilly reissues it for 2027.
Is the Medicare GLP-1 Bridge expiring on 31 December 2026?
No, the Medicare GLP-1 Bridge is not expiring on 31 December 2026, because it was extended to run through 31 December 2027. The Centers for Medicare and Medicaid Services describes the bridge as a time-limited demonstration that began on 1 July 2026 and runs to 31 December 2027, offering eligible Part D beneficiaries a 50 US dollar monthly copay for certain GLP-1 medicines approved for weight loss. The Kaiser Family Foundation explainer, checked on 12 September 2026, notes that the bridge was originally scheduled to end on 31 December 2026 and was later extended, which is most likely the source of the widespread belief that it lapses this year. It does not.
Two limits deserve equal billing with the 50 US dollar figure. The Kaiser Family Foundation notes that the copay does not count toward a beneficiary's Part D deductible or toward the 2,100 US dollar out-of-pocket maximum, and that low-income subsidy cost-sharing help does not apply within the bridge. The same explainer records that the broader BALANCE model for GLP-1s in Medicare Part D has been indefinitely delayed, with CMS stating it would not move forward with that model in Medicare in 2027, which leaves no clear path for obesity-drug coverage in Medicare after the demonstration ends. Eligibility runs through a Part D plan and is based on body weight and health status, and readers who want a plain-language sense of whether they might qualify can start with our short eligibility quiz before checking the official criteria at Medicare's own bridge portal. The honest headline is that the bridge is a two-year stopgap with real gaps, not a permanent benefit, and calling it a 2026 expiry gets both the date and the nature of the programme wrong.
What will Medicare pay for semaglutide after the 1 January 2027 reset?
From 1 January 2027 a negotiated Medicare price replaces the old list price for semaglutide, and that switch, not any card expiry, is the real reset behind this article. CMS announced the second cycle of negotiated prices on 25 November 2025, covering 15 Part D drugs, with the new prices taking effect on 1 January 2027. BioPharma Dive, checked on 12 September 2026, reported the negotiated price for Novo Nordisk's semaglutide products at 274 US dollars for a 30-day supply, against a 2024 list price of 959 US dollars, a discount of roughly 71 per cent. Per-strength maximum fair prices for each presentation are set out in the CMS fact sheet for the 2027 cycle. CMS put the overall effect at a net 44 per cent saving, or about 12 billion US dollars, across the 15 drugs, with about 5.3 million beneficiaries having used them in 2024.
One subtlety keeps the two Medicare tracks separate. The negotiated price flows through the standard Part D benefit, while a beneficiary getting a GLP-1 for weight loss inside the bridge demonstration pays the flat 50 US dollar copay instead. The negotiated figure and the bridge copay are two different mechanisms that happen to arrive around the same time, and conflating them overstates how much any one person saves. The table below sets the before and after side by side.
| Measure | Before, 2024 to 2026 | From 1 January 2027 | Source |
|---|---|---|---|
| Semaglutide list price, 30-day | 959 US dollars | Reference point only | BioPharma Dive |
| Negotiated maximum fair price, 30-day | Not applicable | 274 US dollars | BioPharma Dive, CMS fact sheet |
| Approximate discount | Not applicable | About 71 per cent | BioPharma Dive |
| Bridge demonstration copay | 50 US dollars from 1 July 2026 | 50 US dollars until 31 December 2027 | CMS bridge page |
How strong is the evidence behind each claim here?
Not every claim in this article is equally solid, and the table below grades them so you can weigh each one yourself. The strongest claims rest on a government record or on the issuer's own binding terms. The weakest is the popular idea that all four routes expire on 31 December 2026, which the evidence only partly supports. Where the framing overstates the case, we have marked it down rather than let it stand.
| Claim made in this article | Type of evidence | Strength |
|---|---|---|
| NovoCare 199 dollar intro ends 31 December 2026 | Manufacturer's own offer terms, primary for its own programme | Strong, though the issuer can change terms |
| Zepbound commercial savings card expires 31 December 2026 | Manufacturer's own terms page | Strong on the date, weak on durability since Lilly may amend without notice |
| LillyDirect self-pay journey expires 31 December 2026 | Manufacturer terms print the date, but it is an annual card renewed before | Moderate, likely overstates the real-world effect |
| The Medicare bridge expires 31 December 2026 | Contradicted by CMS and Kaiser Family Foundation, extended to 2027 | Weak, corrected in this article |
| Negotiated semaglutide price is 274 dollars from 1 January 2027 | CMS announcement plus reputable trade press | Strong |
| Bridge copay excludes the deductible and out-of-pocket cap | Kaiser Family Foundation explainer, secondary | Moderate, single reputable secondary source |
The single most important correction in this piece is that only two of the four routes carry a firm 31 December 2026 cliff, the Lilly self-pay card date is soft, and the Medicare bridge does not end this year at all. If you take one thing away, let it be that the real Medicare change is a price that starts on 1 January 2027, not a benefit that stops on 31 December 2026.
Frequently asked questions
Do the manufacturer self-pay prices work with insurance?
No, the NovoCare and LillyDirect self-pay routes are cash-pay channels. The Zepbound self-pay terms require you not to seek reimbursement from any insurer or government programme, and the discounted commercial savings cards are the opposite route, meant for people who do have private insurance.
Can a Medicare beneficiary use the commercial savings cards?
No, the commercial savings cards exclude anyone enrolled in a government-funded programme, and the Zepbound terms name Medicare, Medicare Part D, Medicare Advantage, and Medigap among the exclusions. Medicare beneficiaries would look instead at the bridge demonstration or standard Part D coverage.
Is the 199 dollar Wegovy price a permanent price?
No, it is an introductory price for the first two fills of the two starting doses, after which the standard self-pay price of 349 US dollars a month applies as of 12 September 2026. It is best read as a trial price rather than a maintenance cost.
What happens to the LillyDirect self-pay price if I miss the 45-day refill?
The discounted price falls away and the regular maintenance price applies, according to the Zepbound savings page checked on 12 September 2026. The 45-day refill clock is the condition that actually governs the price, more than the calendar-year card date.
Does the Medicare negotiated price of 274 dollars mean I pay 274 dollars?
Not necessarily, because 274 US dollars is the negotiated maximum fair price for a 30-day supply, not a fixed out-of-pocket amount, and your own cost depends on your plan and on whether you are in the bridge demonstration paying the flat 50 US dollar copay. The two figures come from different mechanisms.
When exactly do the negotiated Medicare prices start?
They take effect on 1 January 2027, according to the CMS announcement of 25 November 2025. That is the morning after the 31 December 2026 date that the marketing around the other programmes points to.
Sources
- CMS, Medicare GLP-1 Bridge programme page, government primary source, checked 12 September 2026.
- CMS press release, Coming Soon, CMS to provide 50 dollar monthly access to GLP-1 medications, government primary source, checked 12 September 2026.
- CMS press release, savings for seniors on 15 major drugs, 25 November 2025, government primary source, checked 12 September 2026.
- CMS fact sheet, negotiated prices for the 2027 cycle, government primary source, checked 12 September 2026.
- Kaiser Family Foundation, what to know about the BALANCE model and the Medicare GLP-1 Bridge, independent research organisation, checked 12 September 2026.
- NovoCare, Wegovy savings, self-pay and home delivery offer page, manufacturer page, not a primary regulatory source, checked 12 September 2026.
- Novo Nordisk press release, introductory self-pay offer at 199 dollars a month, manufacturer announcement, checked 12 September 2026.
- Eli Lilly, Zepbound savings and insurance options page, manufacturer page, not a primary regulatory source, checked 12 September 2026.
- Pharmaceutical Executive, Lilly reduces the price of Zepbound single-dose vials, trade press reporting the manufacturer announcement, checked 12 September 2026.
- BioPharma Dive, CMS sets 2027 Medicare prices for Wegovy, Ozempic and 13 other drugs, trade press reporting the CMS record, checked 12 September 2026.